entvantagedx
1 known investors
Entvantage Dx develops diagnostic tests for ear, nose, and throat illnesses that distinguish bacterial from viral infections, including a kit that identifies major bacterial sinusitis pathogens. The tests are intended to help physicians reduce unnecessary antibiotic prescriptions.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $762.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does entvantagedx do?
- Entvantage Dx develops diagnostic tests for ear, nose, and throat illnesses that distinguish bacterial from viral infections, including a kit that identifies major bacterial sinusitis pathogens. The tests are intended to help physicians reduce unnecessary antibiotic prescriptions.
- Who are entvantagedx's investors?
- entvantagedx's investors include Central Texas Angel Network.